| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy JG Paez, PA Jänne, JC Lee, S Tracy, H Greulich, S Gabriel, P Herman, ... Science 304 (5676), 1497-1500, 2004 | 9980 | 2004 |
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling JA Engelman, K Zejnullahu, T Mitsudomi, Y Song, C Hyland, JO Park, ... science 316 (5827), 1039-1043, 2007 | 4316 | 2007 |
| Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists … NI Lindeman, PT Cagle, MB Beasley, DA Chitale, S Dacic, G Giaccone, ... The Journal of molecular diagnostics 15 (4), 415-453, 2013 | 1386 | 2013 |
| Characterizing the cancer genome in lung adenocarcinoma BA Weir, MS Woo, G Getz, S Perner, L Ding, R Beroukhim, WM Lin, ... Nature 450 (7171), 893, 2007 | 1084 | 2007 |
| Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC AB Turke, K Zejnullahu, YL Wu, Y Song, D Dias-Santagata, E Lifshits, ... Cancer cell 17 (1), 77-88, 2010 | 959 | 2010 |
| EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer JP Koivunen, C Mermel, K Zejnullahu, C Murphy, E Lifshits, AJ Holmes, ... Clinical cancer research 14 (13), 4275-4283, 2008 | 959 | 2008 |
| LKB1 modulates lung cancer differentiation and metastasis H Ji, MR Ramsey, DN Hayes, C Fan, K McNamara, P Kozlowski, C Torrice, ... Nature 448 (7155), 807, 2007 | 844 | 2007 |
| Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population SJ Rodig, M Mino-Kenudson, S Dacic, BY Yeap, A Shaw, JA Barletta, ... Clinical cancer research 15 (16), 5216-5223, 2009 | 669 | 2009 |
| Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or erlotinib DM Jackman, BY Yeap, LV Sequist, N Lindeman, AJ Holmes, VA Joshi, ... Clinical Cancer Research 12 (13), 3908-3914, 2006 | 573 | 2006 |
| A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors T Sasaki, J Koivunen, A Ogino, M Yanagita, S Nikiforow, W Zheng, ... Cancer research 71 (18), 6051-6060, 2011 | 537 | 2011 |
| A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry M Mino-Kenudson, LR Chirieac, K Law, JL Hornick, N Lindeman, EJ Mark, ... Clinical Cancer Research 16 (5), 1561-1571, 2010 | 474 | 2010 |
| Phase II clinical trial of chemotherapy-naive patients>= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer DM Jackman, BY Yeap, NI Lindeman, P Fidias, MS Rabin, J Temel, ... Journal of Clinical Oncology 25 (7), 760-766, 2007 | 412 | 2007 |
| Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing RK Thomas, E Nickerson, JF Simons, PA Jänne, T Tengs, Y Yuza, ... Nature medicine 12 (7), 852, 2006 | 372 | 2006 |
| Differential effects of gefitinib and cetuximab on non–small-cell lung cancers bearing epidermal growth factor receptor mutations T Mukohara, JA Engelman, NH Hanna, BY Yeap, S Kobayashi, ... Journal of the National Cancer Institute 97 (16), 1185-1194, 2005 | 359 | 2005 |
| Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine EM Van Allen, N Wagle, P Stojanov, DL Perrin, K Cibulskis, S Marlow, ... Nature medicine 20 (6), 682, 2014 | 354 | 2014 |
| Acute myeloid leukemia ontogeny is defined by distinct somatic mutations RC Lindsley, BG Mar, E Mazzola, PV Grauman, S Shareef, SL Allen, ... Blood 125 (9), 1367-1376, 2015 | 349 | 2015 |
| Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology … MM Li, M Datto, EJ Duncavage, S Kulkarni, NI Lindeman, S Roy, ... The Journal of molecular diagnostics 19 (1), 4-23, 2017 | 321 | 2017 |
| Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American … NI Lindeman, PT Cagle, DL Aisner, ME Arcila, MB Beasley, EH Bernicker, ... Journal of Thoracic Oncology 13 (3), 323-358, 2018 | 309 | 2018 |
| MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele … L Xu, ZR Hunter, G Yang, Y Zhou, Y Cao, X Liu, E Morra, A Trojani, ... Blood 121 (11), 2051-2058, 2013 | 280 | 2013 |
| Response and resistance in a non–small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib DM Jackman, AJ Holmes, N Lindeman, PY Wen, S Kesari, AM Borras, ... Journal of Clinical Oncology 24 (27), 4517-4520, 2006 | 255 | 2006 |
